Literature DB >> 23780910

Method of variability optimization in pharmacokinetic data analysis.

Tomasz Grabowski1, Jerzy Jan Jaroszewski, Walerian Piotrowski, Małgorzta Sasinowska-Motyl.   

Abstract

For many drugs administered per os, high variability in the concentration-time (C-T) values from first sampling to the phase of distribution may cause difficulty in pharmacokinetic analysis. Therefore, the aim of this study was to propose a method of transformation of C-T data, which would allow significantly reducing the standard deviation (SD) value of observed concentrations, without a statistically significant influence on the value of the mean for each sampling point in group. In the presented study, the lowest value of relative standard deviation of concentrations observed in the elimination phase and the value of precision of the used analytical method, were used to optimize the arithmetic, geometric means, median, and the value of SD obtained after single oral administration of itraconazole in human subjects. Non-compartmental modeling was used to estimate pharmacokinetic parameters. The analysis of SD pharmacokinetic parameters after C-T value optimization indicated more than twice the lower value of SD. After transforming the itraconazole data, lower variability of concentration data gives more selective pharmacokinetics profile in absorption and early distribution phase.

Entities:  

Mesh:

Year:  2013        PMID: 23780910      PMCID: PMC4048666          DOI: 10.1007/s13318-013-0145-x

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  29 in total

1.  Why are pharmacokinetic data summarized by arithmetic means?

Authors:  S A Julious; C A Debarnot
Journal:  J Biopharm Stat       Date:  2000-02       Impact factor: 1.051

2.  An area correction method to reduce intrasubject variability in bioequivalence studies.

Authors:  H Y Abdallah
Journal:  J Pharm Pharm Sci       Date:  1998 May-Aug       Impact factor: 2.327

Review 3.  Noncompartmentally-based pharmacokinetic modeling.

Authors:  P Veng-Pedersen
Journal:  Adv Drug Deliv Rev       Date:  2001-06-11       Impact factor: 15.470

4.  Internal quality control system for non-stationary, non-ergodic analytical processes based upon exponentially weighted estimation of process means and process standard deviation.

Authors:  Rob T P Jansen; Mark Laeven; Wim Kardol
Journal:  Clin Chem Lab Med       Date:  2002-06       Impact factor: 3.694

Review 5.  Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research.

Authors:  Manish Yadav; Pranav S Shrivastav
Journal:  Bioanalysis       Date:  2011-05       Impact factor: 2.681

6.  Estimation of variance for harmonic mean half-lives.

Authors:  F C Lam; C T Hung; D G Perrier
Journal:  J Pharm Sci       Date:  1985-02       Impact factor: 3.534

Review 7.  The potential pharmacological and toxicological impact of P450 screening.

Authors:  R J Riley
Journal:  Curr Opin Drug Discov Devel       Date:  2001-01

8.  Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration.

Authors:  D M Cocchetto; W A Wargin; J W Crow
Journal:  J Pharmacokinet Biopharm       Date:  1980-12

9.  Absolute bioavailability of [14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity.

Authors:  Nick G Coldham; Ai-Qin Zhang; Pauline Key; Maurice J Sauer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

10.  Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.

Authors:  Korbtham Sathirakul; Clark Chan; Leyan Teng; Richard F Bergstrom; Kwee Poo Yeo; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.